但是,要找到新的靶标,就必须将疼痛通路的每个微小的细节都剖析清楚。现任华盛顿大学瘙痒中心主任陈宙峰(Zhou-Feng Chen)领导团队利用小鼠研究了可对特定的化学信号作出反应,并改变细胞行为的细胞表面受体和分子。这一2007年发表在《自然》杂志(Nature)上的研究被众多研究人员一致认为是该领域最重要的进展之一。
The group was the first to find a receptor in the spinal cord that was specific for itching, called gastrin-releasing peptide receptor, or GRPR. The discovery helped to prove that signals for itching and pain travel on different pathways.
该小组首次在脊髓中发现了瘙痒特异性受体,称为胃泌素释放肽受体(gastrin-releasing peptide receptor),简称GRPR。这一发现有助于证明瘙痒和疼痛的信号传导途径并不相同。
In an interview, Dr. Chen said that mice without the receptor — or with the receptor blocked by a drug — did not itch. Nor was the group without a receptor harmed by the lack of it.
陈博士在接受采访时表示,不具备该受体,或该受体被药物阻断的小鼠就不会产生瘙痒的感觉。且无受体组的小鼠并未因此而受到损害。
"If you block function of this receptor alone, you pretty much stop chronic itching," he said.
“仅仅阻断该受体的功能,就几乎足以给慢性瘙痒画上句号,”他说。
【瘙痒和挠痒有什么科学依据吗?】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15